Robocath, a Rouen, France-based company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, raised €5m in funding.
Backers included Go Capital, NCI, Normandie Participations, M Capital and Supernova Invest and new funds Caisse d’Epargne Normandie Innovation, Crédit Agricole Innove en Normandie and Unexo, a subsidiary of the Crédit Agricole group.
The company intends to use the funds for the rollout of its robotic platform in strategic European target markets.
Led by newly hired CEO Lucien Goffart, and founder & president Philippe Bencteux, Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases.
R-One™, the first solution developed by the company, uses technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood.
It received the CE marking in February 2019.